TNDM TANDEM DIABETES CARE INCcompanySEC Filings & Insider Trading Activity 2026
Latest TANDEM DIABETES CARE INC (TNDM) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on February 19, 2026, a 10-Q quarterly report filed on November 6, 2025, an 8-K current report filed on February 27, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for TANDEM DIABETES CARE INC (TNDM) (SEC CIK 1438133), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-K Annual Report AnalysisLatest 10-K (2025-12-31)
Business Overview
- • Core business model: Design, development, and commercialization of advanced insulin delivery and diabetes technology with AID systems featuring Control-IQ+ hybrid closed-loop technology
- • New product emphasis: Expanded commercial availability of Tandem Mobi with Android control (2025) and Control-IQ+ algorithm cleared for type 2 diabetes (18+ years) in 2025
Risk Factors
- • Cybersecurity risk managed by dedicated Incident Management Team led by VP, Cybersecurity with 20+ years industry experience
- • Escalation protocols include disclosure committee and Cybersecurity and Data Privacy Oversight Committee to address significant incidents
Management Discussion & Analysis
- • Revenue $1.015B in 2025, up 8% YoY from $940.2M in 2024; U.S. sales $706.9M (+5%), international $307.8M (+15%)
- • Gross margin 54% in 2025 vs 52% in 2024; operating loss $(187.3M) vs $(99.1M) reflecting higher operating expenses ($733.3M vs $588.7M)
AI 10-Q Quarterly Report AnalysisLatest 10-Q (2025-09-30)
Risk Factors
- • New risk: CMS proposed competitive bidding process and payment changes for insulin pumps (June 30, 2025) could reduce reimbursement and impact revenue recognition
- • Updated competitive risk: Increased adoption of GLP-1 drugs since 2023 negatively impacts insulin therapy market demand
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 1.01: Entry into a Material Definitive Agreement
- • Convertible notes issued Feb 24, 2026 via Rule 144A private placement to qualified institutional buyers
- • Maximum 11,152,410 shares of Common Stock issuable upon conversion at initial max rate of 37.1747 shares per $1,000 principal
Item 8.01: Other Events
- • TNDM launched a convertible notes offering ("the Notes"), announced Feb 23 and priced Feb 25, 2026
- • Proceeds use not fully disclosed here — stated as "expected uses" subject to change, signaling dilution or debt risk for equity holders
Annual Reports Archive10-K
AI-powered analysis of TANDEM DIABETES CARE INC (TNDM) 10-K annual reports filed with SEC EDGAR.
Quarterly Reports Archive10-Q
AI-powered analysis of TANDEM DIABETES CARE INC (TNDM) 10-Q quarterly reports filed with SEC EDGAR.
Recent 8-K FilingsCurrent Reports
AI-powered analysis of TANDEM DIABETES CARE INC (TNDM) 8-K current reports disclosing material events.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | $801.2M | $747.7M | $940.2M | $1.0B |
| Gross Profit | $413.0M | $367.7M | $489.6M | $546.0M |
| Operating Income | — | -$233.2M | -$99.1M | -$187.3M |
| Net Income | — | -$222.6M | -$96.0M | -$204.7M |
| Gross Margin | 51.5% | 49.2% | 52.1% | 53.8% |
| Op. Margin | — | -31.2% | -10.5% | -18.5% |
| Net Margin | — | -29.8% | -10.2% | -20.2% |
| Balance Sheet | ||||
| Total Assets | — | $952.7M | $967.7M | $881.1M |
| Equity | — | $313.6M | $263.1M | $155.2M |
| ROE | — | -71.0% | -36.5% | -131.9% |
Source: XBRL financial data from TANDEM DIABETES CARE INC (TNDM) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Feb 27, 2026 | — | Analysis | — |
8-K | Feb 19, 2026 | — | — | |
10-K | Feb 19, 2026 | Dec 31, 2025 | Analysis | |
8-K | Dec 30, 2025 | — | — | |
10-Q | Nov 6, 2025 | Sep 30, 2025 | Analysis | |
10-Q | Aug 6, 2025 | Jun 30, 2025 | — | |
10-Q | Apr 30, 2025 | Mar 31, 2025 | — | |
10-K | Feb 26, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 6, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 1, 2024 | Jun 30, 2024 | — | |
10-Q | May 2, 2024 | Mar 31, 2024 | — | |
10-K | Feb 21, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 1, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 3, 2023 | Jun 30, 2023 | — | |
10-Q | May 3, 2023 | Mar 31, 2023 | — | |
10-K | Feb 22, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 2, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 3, 2022 | Jun 30, 2022 | — | |
10-Q | May 4, 2022 | Mar 31, 2022 | — | |
10-K | Feb 22, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 3, 2021 | Sep 30, 2021 | — | |
10-Q | Aug 4, 2021 | Jun 30, 2021 | — | |
10-Q | May 5, 2021 | Mar 31, 2021 | — | |
10-K | Feb 24, 2021 | Dec 31, 2020 | — | |
10-Q | Nov 5, 2020 | Sep 30, 2020 | — |
Frequently Asked Questions
What are the latest TNDM SEC filings in 2026?
TANDEM DIABETES CARE INC (TNDM) has filed a 10-K annual report on February 19, 2026, a 10-Q quarterly report on November 6, 2025, an 8-K current report on February 27, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did TNDM file its most recent 10-K annual report?
TANDEM DIABETES CARE INC (TNDM) filed its most recent 10-K annual report on February 19, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view TNDM 10-Q quarterly reports?
TANDEM DIABETES CARE INC (TNDM)'s most recent 10-Q quarterly report was filed on November 6, 2025. SignalX displays every TNDM 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has TNDM filed recently?
TANDEM DIABETES CARE INC (TNDM)'s most recent 8-K was filed on February 27, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find TNDM insider trading activity (Form 4)?
SignalX aggregates every TNDM Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does TNDM file with the SEC?
TANDEM DIABETES CARE INC (TNDM) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new TNDM filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for TANDEM DIABETES CARE INC (TNDM).
What is TNDM's SEC CIK number?
TANDEM DIABETES CARE INC (TNDM)'s SEC CIK (Central Index Key) number is 1438133. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1438133 to look up all TNDM filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find TNDM return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from TANDEM DIABETES CARE INC (TNDM) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of TANDEM DIABETES CARE INC SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 44+ filings.